Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mannitol versus 3% hypertonic saline for coagulation effects in supratentorial brain tumor surgery
IRCT20210506051200N2Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Dec 2022
- Modality
- Small Molecules, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label trial of Bronchitol and hypertonic saline in brain neoplasm (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Blood coagulation by PFA-100, Platelet function and 1 more. Started Dec 2022; status: completed.
02
Drugs
Bronchitolhypertonic saline
03
Conditions
brain neoplasm
Beyond the preview
Go deeper on IRCT20210506051200N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210506051200N2.